[1]
|
Lu, T., Yang, X., Huang, Y., Zhao, M., Li, M., Ma, K., et al. (2019) Trends in the Incidence, Treatment, and Survival of Patients with Lung Cancer in the Last Four Decades. Cancer Management and Research, 11, 943-953.
https://doi.org/10.2147/CMAR.S187317
|
[2]
|
Fehrenbacher, L., von Pawel, J., Park, K., Rittmeyer, A., Gandara, D.R., Ponce Aix, S., et al. (2018) Updated Efficacy Analysis Including Secondary Population Results for Oak: A Ran-domized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 1156-1170. https://doi.org/10.1016/j.jtho.2018.04.039
|
[3]
|
杨亚冰, 田丰. 小细胞肺癌的靶向治疗与免疫治疗的研究进展[J]. 癌症进展, 2020, 18(14): 1424-1426.
|
[4]
|
蒋小雯, 张沂平. 拓扑替康周方案在实体肿瘤中应用的研究进展[J]. 肿瘤学杂志, 2016, 22(8): 673-678.
|
[5]
|
张也, 张艳, 贾刚. 小细胞肺癌的治疗现状及进展[J]. 中国医药指南, 2019, 17(26): 23-25+29.
|
[6]
|
Roos, W.P., Thomas, A.D. and Kaina, B. (2016) DNA Damage and the Balance between Survival and Death in Cancer Biology. Nature Re-views Cancer, 16, 20-33. https://doi.org/10.1038/nrc.2015.2
|
[7]
|
Rudin, C.M., Brambilla, E., Faivre-Finn, C. and Sage, J. (2021) Small-Cell Lung Cancer. Nature Reviews Disease Primers, 7, Article No. 3. https://doi.org/10.1038/s41572-020-00235-0
|
[8]
|
赵明芳, 刘云鹏. 小细胞肺癌靶向药物研究进展[J]. 中国处方药, 2013, 9(5): 36-38.
|
[9]
|
Donawho, C.K., Luo, Y., Luo, Y., Penning, T.D., Bauch, J.L., Bouska, J.J., et al. (2007) Abt-888, an Orally Active Poly (Adp-Ribose) Polymerase Inhibitor That Potentiates DNA-Damaging Agents in Preclin-ical Tumor Models. Clinical Cancer Research, 13, 2728-2737. https://doi.org/10.1158/1078-0432.CCR-06-3039
|
[10]
|
Farago, A.F., Yeap, B.Y., Stanzione, M., Hung, Y.P., Heist, R.S., Marcoux, J.P., et al. (2019) Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discovery, 9, 1372-1387.
https://doi.org/10.1158/2159-8290.CD-19-0582
|
[11]
|
Nikonova, A.S., Astsaturov, I., Serebriiskii, I.G., Dunbrack Jr., R.L. and Golemis, E.A. (2013) Aurora a Kinase (Aurka) in Normal and Pathological Cell Division. Cellular and Molecular Life Sciences, 70, 661-687.
https://doi.org/10.1007/s00018-012-1073-7
|
[12]
|
Melichar, B., Adenis, A., Lockhart, A.C., Bennouna, J., Dees, E.C., Kayaleh, O., et al. (2015) Safety and Activity of Alisertib, an Investigational Aurora Kinase A Inhibitor, in Patients with Breast Cancer, Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer, Head and Neck Squamous-Cell Carcinoma, and Gastro-Oesophageal Adenocarcinoma: A Five-Arm Phase 2 Study. The Lancet Oncology, 16, 395-405. https://doi.org/10.1016/S1470-2045(15)70051-3
|
[13]
|
Tiseo, M., Boni, L., Ambrosio, F., Camerini, A., Baldini, E., Cinieri, S., et al. (2017) Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide with or without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Clinical Oncology, 35, 1281-1287.
https://doi.org/10.1200/JCO.2016.69.4844
|
[14]
|
秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9): 841-847.
|
[15]
|
杜娟, 刘宝瑞. 阿帕替尼治疗二例晚期难治性胃癌的临床观察[J]. 中华肿瘤杂志, 2016, 38(8): 636-638.
|
[16]
|
文峰, 向燕, 王雷. 阿帕替尼片治疗晚期胃癌的临床研究[J]. 中国临床药理学杂志, 2017, 33(7): 589-591.
|
[17]
|
Lin, B., Song, X., Yang, D., Bai, D., Yao, Y. and Lu, N. (2018) Anlotinib Inhibits Angiogenesis via Suppressing the Activation of VEGFR2, PDGFRβ and FGFR1. Gene, 654, 77-86. https://doi.org/10.1016/j.gene.2018.02.026
|
[18]
|
Sun, Y., Niu, W., Du, F., Du, C., Li, S., Wang, J., et al. (2016) Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Pa-tients with Advanced Refractory Solid Tumors. Journal of Hematology & Oncology, 9, Article No. 105. https://doi.org/10.1186/s13045-016-0332-8
|
[19]
|
Cheng, Y., Wang, Q., Li, K., Shi, J., Wu, L., Han, B., et al. (2018) OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Dou-ble-Blind Phase 2 Trial. Journal of Thoracic Oncology, 13, S351-S352. https://doi.org/10.1016/j.jtho.2018.08.308
|
[20]
|
王伙刚, 洪波, 林文楚. 小细胞肺癌靶向治疗研究进展[J]. 中国药理学通报, 2017, 33(10): 1333-1337.
|
[21]
|
石远凯, 孙燕, 于金明, 丁翠敏, 马智勇, 王子平, 等. 中国肺癌脑转移诊治专家共识(2017年版) [J]. 中国肺癌杂志, 2017, 20(1): 1-13.
|
[22]
|
Rudin, C.M., Pictanza, M.C., Baucr, T.M., Spigel, D.R., Ready, N., Morgensztern, D., et al. (2016) Safcty and Efficacy of Single-Agent Rovalpituzumab-tesirine(Sc16ld6.5), a Deltalike Protein a (Dll3)-Targeted Antibody Lung Conjugate(ADC) in Recurrent or Re-Factory Small Cell Lung Cancer(SCLC). Journal of Clinical Oncology, 34, LBA8505.
https://doi.org/10.1200/JCO.2016.34.15_suppl.LBA8505
|
[23]
|
Shah, M.H., Lorigan, P.O., Brien, M.E.R., Fossella, F.V., Moore, K.N., Bhatia, S., et al. (2016) Phase I Study of Imgn901, a Cd56-Targeting Antibody-Drug Conjugate, in Patients with Cd56-Positive Solid Tumors. Investigational New Drugs, 34, 290-299. https://doi.org/10.1007/s10637-016-0336-9
|
[24]
|
王鑫, 张毅, 胡牧, 王若天, 刘磊, 钱坤, 等. TTF-1、CD56、P40免疫组化标志物及其他临床特征与小细胞肺癌预后相关性研究[J]. 中国肺癌杂志, 2017, 20(8): 522-527.
|
[25]
|
张力. 小细胞肺癌治疗进展[J]. 癌症进展, 2013, 11(2): 99-105.
|
[26]
|
吕晓鹏. 小细胞肺癌分子靶向治疗进展[J]. 世界最新医学信息文摘, 2019, 19(23): 80-81.
https://doi.org/10.19613/j.cnki.1671-3141.2019.23.043
|
[27]
|
周毅. 小细胞肺癌靶向药物治疗进展[J]. 中外医学研究, 2019, 17(12): 186-188.
https://doi.org/10.14033/j.cnki.cfmr.2019.12.088
|
[28]
|
Salama, A.K. and Hodi, F.S. (2011) Cytotoxic T-Lymphocyte-Associated Antigen-4. Clinical Cancer Research, 17, 4622-4628. https://doi.org/10.1158/1078-0432.CCR-10-2232
|
[29]
|
Hardy-Werbin, M., Arpí, O., Taus, A., Rocha, P., Jo-seph-Pietras, D., Nolan, L., et al. (2017) Assessment of Neuronal Autoantibodies in Patients with Small Cell Lung Can-cer Treated with Chemotherapy with or without Ipilimumab. OncoImmunology, 7, Article ID: e1395125. https://doi.org/10.1080/2162402X.2017.1395125
|
[30]
|
Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., et al. (2019) PL02.11 Overall Survival with Durvalumab plus Etokposide-Platinum in First-Line Ex-tensive-Stage SCLC: Results from the Caspian Study. Journal of Thoracic Oncology, 14, S7-S8. https://doi.org/10.1016/j.jtho.2019.08.061
|
[31]
|
Toor, S.M., Nair, V.S., Decock, J. and Elkord, E. (2020) Immune Checkpoints in the Tumor Microenvironment. Seminars in Cancer Biology, 65, 1-12. https://doi.org/10.1016/j.semcancer.2019.06.021
|
[32]
|
Keeping, S.T., Cope, S., Chan, K., Wilson, F.R., Jansen, J.P., Penrod, J.R., et al. (2020) Comparative Effectiveness of Nivolumab versus Standard of Care for Third-Line Patients with Small-Cell Lung Cancer. Journal of Comparative Effectiveness Research, 9, 1275-1284. https://doi.org/10.2217/cer-2020-0134
|
[33]
|
Goldman, J.W., Garassino, M.C., Chen, Y., Özgüroğlu, M., Dvorkin, M., Trukhin, D., et al. (2020) Patient-Reported Outcomes with First-Line Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer (Caspian): A Randomized, Controlled, Open-Label, Phase III Study. Lung Cancer, 149, 46-52.
https://doi.org/10.1016/j.lungcan.2020.09.003
|
[34]
|
廖龙飞, 杨青青, 陈燕. 免疫检查点抑制剂联合治疗在小细胞肺癌中的研究进展[J]. 肿瘤预防与治疗, 2020, 33(9): 806-812. https://doi.org/10.3969/j.issn.1674-0904.2020.09.013
|
[35]
|
Horn, L., Reck, M., Mok, T., Sánchez, A., De Boer, R., Andric, Z., et al. (2016) PS01.57: Impower133: A Phase I/III Study of 1l Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC Topic: Medical Oncology. Journal of Thoracic Oncology, 11, S305-S306. https://doi.org/10.1016/j.jtho.2016.09.092
|
[36]
|
Mansfield, A.S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., et al. (2020) Safety and Patient-Reported Outcomes of Atezolizumab, Carboplat-in, and Etoposide in Extensive-Stage Small-Cell Lung Cancer (Im-Power133): A Randomized Phase I/III Trial. Annals of Oncology, 31, 310-317.
https://doi.org/10.1016/j.annonc.2019.10.021
|
[37]
|
Kim, Y.J., Keam, B., Ock, C.Y., Song, S., Kim, M., Kim, S.H., et al. (2019) A Phase II Study of Pembrolizumab and Paclitaxel in Patients with Relapsed or Refractory Small-Cell Lung Cancer. Lung Cancer, 136, 122-128.
https://doi.org/10.1016/j.lungcan.2019.08.031
|
[38]
|
Hu, J., Wang, Y., Zhang, Y., Yu, Y., Chen, H., Liu, K., et al. (2019) Comprehensive Genomic Pro-Filing of Small Cell Lung Cancer in Chinese Patients and the Implications for Therapeutic Potential. Cancer Medicine, 8, 4338-4347.
https://doi.org/10.1002/cam4.2199
|
[39]
|
Chiappori, A.A., Soliman, H., Janssen, W.E., Antonia, S.J. and Gabrilo-vich, D.I. (2010) INGN-225: A Dendritic Cell-Based p53 Vaccine (Ad. p53-Dc) in Small Cell Lung Cancer: Observed Association between Immune Response and Enhanced Chemotherapy Effect. Expert Opinion on Biological Therapy, 10, 983-991.
https://doi.org/10.1517/14712598.2010.484801
|
[40]
|
Zarogoulidis, K., Ziogas, E., Boutsikou, E., Zarogoulidis, P., Darwiche, K., Kontakiotis, T., et al. (2013) Immunomodifiers in Combination with Conventional Chemotherapy in Small Cell Lung Cancer: A Phase II, Randomized Study. Drug Design, Development and Therapy, 7, 611-617. https://doi.org/10.2147/DDDT.S43184
|